We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
+3.16%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.43B
AUM Growth
+$53M
Cap. Flow
+$230M
Cap. Flow %
9.46%
Top 10 Hldgs %
47.1%
Holding
78
New
18
Increased
12
Reduced
15
Closed
20

Top Buys

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$82.2M
2
ALKS icon
Alkermes
ALKS
+$81.7M
3
GPCR icon
Structure Therapeutics
GPCR
+$62.2M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$61.1M
5
GERN icon
Geron
GERN
+$55.2M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$85.5M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$68.4M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$56.9M
4
IMVT icon
Immunovant
IMVT
+$39.5M
5
ALBO
Albireo Pharma Inc
ALBO
+$36.8M

Sector Composition

Rank Sector Weight
1 Healthcare 96.59%
2 Miscellaneous 3.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTX icon
51
Nkarta
NKTX
$207M
$4.81M 0.2%
1,354,200
– –
GHRS icon
52
GH Research
GHRS
$1.9B
$3.99M 0.16%
499,400
– –
IMUX icon
53
Immunic
IMUX
$141M
$3.76M 0.15%
+252,424
New +$4.69M
TSVT
54
DELISTED
2seventy bio
TSVT
$3.57M 0.15%
+350,000
New +$4M
IPSC icon
55
Century Therapeutics
IPSC
$355M
$3.55M 0.15%
1,022,892
+327,047
+47% +$1.44M
IMGN
56
PUT
DELISTED
Immunogen Inc
IMGN
$1.64M 0.07%
+428,100
New +$1.82M
NKTR icon
57
Nektar Therapeutics
NKTR
$2.28B
$1.23M 0.05%
+116,217
New +$3.52M
ETNB
58
PUT
DELISTED
89bio
ETNB
$67K ﹤0.01%
+4,400
New +$57.4K
ASMB icon
59
Assembly Biosciences
ASMB
$536M
– –
-152,786
Closed -$2.38M
ASND icon
60
CALL
Ascendis Pharma A/S
ASND
$16.2B
– –
-249,300
Closed -$30.4M
ASND icon
61
Ascendis Pharma A/S
ASND
$16.2B
– –
-700,000
Closed -$85.5M
AUPH icon
62
Aurinia Pharmaceuticals
AUPH
$2.22B
– –
-324,238
Closed -$1.4M
BMRN icon
63
BioMarin Pharmaceuticals
BMRN
$12.6B
– –
-189,800
Closed -$19.6M
CRNX
64
DELISTED
Crinetics Pharmaceuticals
CRNX
– –
-1,048,829
Closed -$19.2M
DNTH icon
65
Dianthus Therapeutics
DNTH
$5.83B
– –
-187,500
Closed -$1.19M
ESPR
66
DELISTED
Esperion Therapeutics
ESPR
– –
-4,000,000
Closed -$24.9M
FULC icon
67
Fulcrum Therapeutics
FULC
$291M
– –
-768,607
Closed -$5.6M
HOOK
68
DELISTED
HOOKIPA Pharma
HOOK
– –
-124,037
Closed -$1M
PTGX icon
69
Protagonist Therapeutics
PTGX
$9.3B
– –
-871,493
Closed -$9.51M
RNAM
70
DELISTED
Avidity Biosciences
RNAM
– –
-300,000
Closed -$6.66M
SNDX icon
71
Syndax Pharmaceuticals
SNDX
$1.57B
– –
-500,000
Closed -$12.7M
SRPT icon
72
Sarepta Therapeutics
SRPT
$2.13B
– –
-528,244
Closed -$68.4M
THRD
73
DELISTED
Third Harmonic Bio
THRD
– –
-445,572
Closed -$1.92M
VKTX icon
74
Viking Therapeutics
VKTX
$3.58B
– –
-610,083
Closed -$5.73M
RETA
75
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-12,600
Closed -$479K
1 2
3
4

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Deep Track Capital held 78 positions worth $2.43B, up 2.2% from $2.38B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Deep Track Capital deployed $230M of net new capital in Q1 2023, opening 18 new positions and adding to 12 existing holdings. Its largest new stake was Intra-Cellular Therapies Inc.: 1,700,000 shares worth $92.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Immunovant, an estimated $39.5M trimmed.

  • Deep Track Capital's largest Q1 2023 buy was Intra-Cellular Therapies Inc.: 1,700,000 shares worth $92.1M.
  • Deep Track Capital added most to Ionis Pharmaceuticals in Q1 2023, an estimated $61.1M increase.
  • Deep Track Capital's biggest Q1 2023 reduction was Immunovant, cutting an estimated $39.5M.
  • Deep Track Capital fully exited Ascendis Pharma A/S in Q1 2023, selling an estimated $85.5M.
  • Deep Track Capital's ten largest holdings make up 47% of its $2.43B portfolio in Q1 2023.
  • Deep Track Capital opened 18 new positions and closed 20 in Q1 2023.
  • Deep Track Capital's portfolio value rose 2.2% quarter-over-quarter to $2.43B.

Based on Deep Track Capital's 13F filing for Q1 2023, filed 15 May 2023.